glp-1 analog peptides
30% More Effective With Semaglutide
30% More Effective With Semaglutide Clinicians should prioritize tirzepatide over semaglutide for MC4R-deficient obesity because it delivers about 30% more weight loss in recent phase-III data. The study compared identical dosing periods and showed a clear advantage for tirzepatide, prompting a re-evaluation of first-line therapy. This shift matters for patients